每周新鲜药闻,百诚与您共同关注!【药闻医讯一周速览】国家药监局药审中心关于发布《化学药品仿制药上市许可申请模块二药学资料撰写要求(试行)》的通告(2025年第32号);12亿美元!艾伯维进一步拓展CNS产品线;全球首款!脐血造血干细胞疗法获批上市……政策简报国家药监局药审中心关于发布《疫苗佐剂非临床研究技术指导原则》的通告(2025年第36号)8月28日,为更好地指导疫苗佐剂的非临床研究和评价,...
Source Link每周新鲜药闻,百诚与您共同关注!【药闻医讯一周速览】国家药监局药审中心关于发布《化学药品仿制药上市许可申请模块二药学资料撰写要求(试行)》的通告(2025年第32号);12亿美元!艾伯维进一步拓展CNS产品线;全球首款!脐血造血干细胞疗法获批上市……政策简报国家药监局药审中心关于发布《疫苗佐剂非临床研究技术指导原则》的通告(2025年第36号)8月28日,为更好地指导疫苗佐剂的非临床研究和评价,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.